A phase II study of docetaxel plus ramcirumab with pegfilgrastim in treated patients with advanced non-small cell lung cancer
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000027223
- Lead Sponsor
- Osaka City University Department of Respiratory Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 28
Not provided
1)Interstitial pneumonia , fibroid lung confirmed by CT. 2)History of serious drug allergy 3)Patient with much ascetic fluid, pleural effusion, cardiac effusion. 4)Obvious tumor invasion to main thoracic vessel 5)Have lung cavity 6)Histoly of hemoptysis within two months 7)History of thoracic radiation therapy 8)Tumor invasion to central airway 9)Uncontrolled coagulation disorder or receiving anticoagulant drugs 10)Have inflammatory bowel disease 11)History of thrombosis 12)Have active wounds 13)Uncontrollable hypertension 14)Proteinuria 15)Patient with active infection 16)Symptomatic brain metastases 17)Patient with active double cancers 18)Have active severe heart diseases 19)Patient with impaired mental status 20)Pregnancy 21)Other ineligible status judged by attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of febrile neutropenia during all cycles of ramucirumab plus docetaxel therapy
- Secondary Outcome Measures
Name Time Method Response rate Overall survival Progression free survival Adverse events